Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncobiologics ONSI.W

Healthcare Biotechnology
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ONSI.W)

Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update

GlobeNewswire August 13, 2021

Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference

GlobeNewswire August 11, 2021

Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD

GlobeNewswire August 3, 2021

Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer

GlobeNewswire July 7, 2021

Outlook Therapeutics Announces Inclusion in the Russell 2000® Index

GlobeNewswire June 14, 2021

Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

GlobeNewswire June 8, 2021

Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010

GlobeNewswire May 27, 2021

Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update

GlobeNewswire May 14, 2021

Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021

GlobeNewswire May 12, 2021
View More News ››

Opinion & Analysis (NDAQ:ONSI.W)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ONSI.W)

it's a buy today for me

playing this one again,so glta shareholders.
coolfooldumbguy - January 2, 2020

played this one before

last week it was available for $1.53 per share and,sold it for a profit at $3 per share this week,so it was almost a double for me glta...
coolfooldumbguy - May 22, 2019
View more Bullboard ››

Gemina Laboratories Ltd.

Gemina Laboratories Ltd.

Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary ...
View More »